- By admin
- By March 17, 2026
Financial statements, Second Quarter 2026
Page 1/ 15
Zoom 100%
Helix BioPharma: Financial statements, Second Quarter 2026
Story so far
- Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
- Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025
- Helix BioPharma Corp. Announces Fiscal 2025 Year-End Results
Earlier from Helix BioPharma
- Helix BioPharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Six-Month Periods Ended January 31, 2026
- Helix BioPharma Corp. Announces Presentation at 16th Annual World ADC London
- Helix Biopharma Corp. Extends LEUMUNA Option with metaShape Pharma for Adipose Tissue-Related and Metabolic Diseases
- Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting
- Helix BioPharma Corp. Announces Filing of Interim Financial Statements as of and for the Three-Month Period Ended October 31, 2025
Later from Helix BioPharma
- Helix Biopharma Corp. Announces Strategic Board and Governance Appointments to Support Financing and Nasdaq Uplisting Strategy
- Helix BioPharma Corp. Announces Grant and Cancellation of Stock Options
- Helix BioPharma Corp. Announces Closing of Private Placement of Convertible Debentures
- Helix Biopharma Corp. Announces Financial Results and Filing of Interim Financial Statements as of and for the Three- and Nine-Month Periods Ended April 30, 2026
- Q3 2026 MD&A | Management’s discussion and analysis of financial condition and results of operations
Follow Helix BioPharma into a list and get an email when it puts out news.
Follow Helix BioPharma